CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Financials Chongqing Zhifei Biological Products Co., Ltd.
Equities
300122
CNE100000V20
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.7 CNY | +2.50% |
|
-11.83% | -41.58% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 79,456 | 236,656 | 199,360 | 140,528 | 146,664 | 85,458 | - | - |
| Enterprise Value (EV) 1 | 80,690 | 238,093 | 195,858 | 139,911 | 143,334 | 77,188 | 71,070 | 62,629 |
| P/E ratio | 33.6 x | 71.7 x | 19.5 x | 18.6 x | 18.2 x | 9.58 x | 6.82 x | 7.9 x |
| Yield | 1.01% | 0.34% | 0.48% | 0.57% | 1.31% | 1.88% | 1.9% | 2.24% |
| Capitalization / Revenue | 7.5 x | 15.6 x | 6.5 x | 3.67 x | 2.77 x | 1.51 x | 1.29 x | 1.45 x |
| EV / Revenue | 7.62 x | 15.7 x | 6.39 x | 3.66 x | 2.71 x | 1.36 x | 1.07 x | 1.06 x |
| EV / EBITDA | 27.7 x | 59.1 x | 15.8 x | 15.4 x | 14.8 x | 6.87 x | 5.31 x | 4.73 x |
| EV / FCF | 102 x | 89.2 x | 29.8 x | 261 x | 17.8 x | 38.9 x | 9.13 x | 5.19 x |
| FCF Yield | 0.98% | 1.12% | 3.36% | 0.38% | 5.6% | 2.57% | 11% | 19.3% |
| Price to Book | 13.8 x | 28.7 x | 11.3 x | 5.8 x | 4.66 x | 2.17 x | 1.64 x | 1.47 x |
| Nbr of stocks (in thousands) | 2,400,000 | 2,400,000 | 2,400,000 | 2,400,000 | 2,400,000 | 2,393,790 | - | - |
| Reference price 2 | 33.11 | 98.61 | 83.07 | 58.55 | 61.11 | 35.70 | 35.70 | 35.70 |
| Announcement Date | 2/27/20 | 2/21/21 | 2/8/22 | 3/20/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10,587 | 15,190 | 30,652 | 38,264 | 52,918 | 56,591 | 66,406 | 58,978 |
| EBITDA 1 | 2,910 | 4,027 | 12,394 | 9,079 | 9,700 | 11,237 | 13,376 | 13,235 |
| EBIT 1 | 2,814 | 3,895 | 12,000 | 8,758 | 9,373 | 10,198 | 14,429 | 11,183 |
| Operating Margin | 26.57% | 25.64% | 39.15% | 22.89% | 17.71% | 18.02% | 21.73% | 18.96% |
| Earnings before Tax (EBT) 1 | 2,765 | 3,854 | 11,931 | 8,718 | 9,342 | 10,529 | 14,779 | 15,607 |
| Net income 1 | 2,366 | 3,301 | 10,209 | 7,539 | 8,070 | 9,061 | 12,888 | 11,465 |
| Net margin | 22.35% | 21.73% | 33.3% | 19.7% | 15.25% | 16.01% | 19.41% | 19.44% |
| EPS 2 | 0.9860 | 1.376 | 4.254 | 3.141 | 3.362 | 3.726 | 5.237 | 4.521 |
| Free Cash Flow 1 | 794.3 | 2,670 | 6,576 | 536.6 | 8,030 | 1,986 | 7,784 | 12,078 |
| FCF margin | 7.5% | 17.58% | 21.45% | 1.4% | 15.18% | 3.51% | 11.72% | 20.48% |
| FCF Conversion (EBITDA) | 27.29% | 66.31% | 53.06% | 5.91% | 82.79% | 17.67% | 58.19% | 91.26% |
| FCF Conversion (Net income) | 33.56% | 80.87% | 64.41% | 7.12% | 99.51% | 21.92% | 60.39% | 105.35% |
| Dividend per Share 2 | 0.3333 | 0.3333 | 0.4000 | 0.3333 | 0.8000 | 0.6698 | 0.6796 | 0.7990 |
| Announcement Date | 2/27/20 | 2/21/21 | 2/8/22 | 3/20/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 8,824 | 8,841 | 9,513 | 9,470 | 10,441 | 11,173 | 13,273 | 14,826 | 13,646 | 11,396 | 12,505 | 15,632 | 15,632 | 11,341 | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | - | 2,482 | 3,723 | 3,723 | - | - |
| EBIT 1 | - | 2,126 | 2,269 | 2,105 | 2,142 | 2,242 | 2,397 | 2,711 | 2,668 | 1,738 | 1,737 | 2,730 | 2,921 | 3,089 | 2,292 | - |
| Operating Margin | - | 24.09% | 25.67% | 22.12% | 22.62% | 21.47% | 21.45% | 20.43% | 18% | 12.73% | 15.24% | 21.83% | 18.69% | 19.76% | 20.21% | - |
| Earnings before Tax (EBT) 1 | - | - | - | 2,090 | 2,129 | 2,235 | 2,392 | 2,570 | 2,657 | 1,723 | 1,734 | 2,403 | 3,604 | 3,604 | - | - |
| Net income 1 | 5,491 | - | - | 1,806 | 1,878 | 1,932 | 2,032 | 2,228 | 2,270 | 1,540 | 1,458 | 2,078 | 3,117 | 3,117 | - | - |
| Net margin | - | - | - | 18.99% | 19.83% | 18.5% | 18.19% | 16.79% | 15.31% | 11.28% | 12.79% | 16.62% | 19.94% | 19.94% | - | - |
| EPS 2 | - | 0.7533 | - | 0.7533 | 0.7800 | 0.8067 | 0.8467 | 0.9283 | 0.9400 | 0.6400 | 0.6090 | 0.8700 | 0.9300 | 1.180 | 0.8400 | - |
| Dividend per Share 2 | - | 0.4000 | - | - | - | - | - | - | - | - | - | 0.1148 | 0.1148 | 0.1148 | 0.1320 | 0.1320 |
| Announcement Date | 8/29/21 | 2/8/22 | 4/27/22 | 8/29/22 | 10/27/22 | 3/20/23 | 4/19/23 | 8/28/23 | 10/26/23 | 4/22/24 | 4/22/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 1,234 | 1,437 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 3,502 | 617 | 3,330 | 8,270 | 14,389 | 22,829 |
| Leverage (Debt/EBITDA) | 0.424 x | 0.3568 x | - | - | - | - | - | - |
| Free Cash Flow 1 | 794 | 2,670 | 6,576 | 537 | 8,030 | 1,986 | 7,784 | 12,079 |
| ROE (net income / shareholders' equity) | 47.7% | 46.3% | 78% | 36.1% | 29.1% | 26.6% | 26.1% | 21.3% |
| ROA (Net income/ Total Assets) | 26.7% | 25.2% | 45.1% | - | - | 17.6% | 16.7% | 13.5% |
| Assets 1 | 8,876 | 13,079 | 22,648 | - | - | 51,484 | 77,097 | 84,923 |
| Book Value Per Share 2 | 2.390 | 3.440 | 7.360 | 10.10 | 13.10 | 16.40 | 21.80 | 24.30 |
| Cash Flow per Share 2 | 0.5700 | 1.460 | 3.540 | 0.8300 | 3.750 | 2.930 | 3.900 | - |
| Capex 1 | 573 | 827 | 1,932 | 1,452 | 966 | 1,064 | 1,573 | 1,539 |
| Capex / Sales | 5.41% | 5.44% | 6.3% | 3.8% | 1.83% | 1.88% | 2.37% | 2.61% |
| Announcement Date | 2/27/20 | 2/21/21 | 2/8/22 | 3/20/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
35.7
CNY
Average target price
62.47
CNY
Spread / Average Target
+74.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.58% | 11.51B | |
| -4.06% | 86.13B | |
| +1.97% | 39.82B | |
| +56.59% | 25.23B | |
| -14.82% | 15.36B | |
| -8.82% | 11.95B | |
| -16.29% | 11.6B | |
| +6.14% | 8.71B | |
| -7.02% | 8.12B | |
| +0.95% | 7.72B |
- Stock Market
- Equities
- 300122 Stock
- Financials Chongqing Zhifei Biological Products Co., Ltd.
